corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 7251

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: news

Industry Insider: Some doctors actually say they don't see enough sales reps
The New Jersey Star Ledger 2006 Oct 31
http://www.nj.com/business/ledger/index.ssf?/base/business-0/116668016329040.xml&coll=1


Abstract:

To hear some doctors tell it, if you’ve seen one drug company sales rep, you’ve seen them all.

Turns out, not every doctor feels that way. In fact, 52 percent of physicians think the number of pharmaceutical sales reps calling on them is appropriate, according to a survey of more than 4,000 physicians conducted by Verispan, a market-research firm.

Just who are these doctors?

The survey found general surgeons, emergency medicine physicians, anesthesiologists and orthopedic surgeons most often reported there aren’t enough sales reps calling on them. Each group reported seeing an average of two or fewer reps per week.

There were exceptions, though. Forty-one percent of general practitioners and family medicine doctors and 35 percent of internists reported there are more reps than necessary or far too many reps in the field. They also reported seeing a higher-than-average number of reps each week — 10.

— Ed Silverman

Analyst sees great things ahead

A combination of strong prescription growth and corporate restructuring will push pharmaceutical companies’ fourth-quarter results beyond analysts’ expectations, according to a Bear Stearns report issued this week.

Bear Stearns analyst John Boris wrote that he expected five of the six drugmakers he follows to beat consensus estimates and he reiterated his “overweight” sector rating for the group.

Boris wrote that the new Medicare drug benefit is driving total prescription growth for the companies. He said prescription growth was up 10.5 percent for the quarter so far, compared with an 8.6 percent growth rate in the third quarter. Prescriptions for cholesterol drugs, antidepressants, diabetes treatments and erectile dysfunction pills were especially noteworthy.

Foreign exchange rates should positively affect sales in the quarter, Boris wrote. He also said restructuring efforts by the companies will help boost earnings.

He wrote that Wyeth, Pfizer, Bristol-Myers Squibb, Eli Lilly and Schering-Plough will beat estimates, while Merck will meet analyst expectations.

— Associated Press

FDA approves J&J schizophrenia drug

The Food and Drug Administration approved a long-lasting version of Johnson & Johnson’s blockbuster schizophrenia treatment Risperdal, a key product for the company.

The once-daily treatment, called Invega, is designed to deliver the active ingredient in Risperdal through a technology that allows the drug to remain in the body over a longer period of time.

“Schizophrenia can be a devastating illness requiring lifelong medication and professional counseling,” said Douglas Throckmorton, deputy director of the FDA’s Center for Drug Evaluation and Research.

Invega, whose chemical name is paliperidone, is considered by some to be the most important drug in J&J’s pipeline. It will be marketed in the United States by the company’s Janssen unit.

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








Far too large a section of the treatment of disease is to-day controlled by the big manufacturing pharmacists, who have enslaved us in a plausible pseudo-science...
The blind faith which some men have in medicines illustrates too often the greatest of all human capacities - the capacity for self deception...
Some one will say, Is this all your science has to tell us? Is this the outcome of decades of good clinical work, of patient study of the disease, of anxious trial in such good faith of so many drugs? Give us back the childlike trust of the fathers in antimony and in the lancet rather than this cold nihilism. Not at all! Let us accept the truth, however unpleasant it may be, and with the death rate staring us in the face, let us not be deceived with vain fancies...
we need a stern, iconoclastic spirit which leads, not to nihilism, but to an active skepticism - not the passive skepticism, born of despair, but the active skepticism born of a knowledge that recognizes its limitations and knows full well that only in this attitude of mind can true progress be made.
- William Osler 1909